



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/086,294
		Filing Date	February 28, 2002
		First Named Inventor	Nielsen, Loretta
		Art Unit	1635 1632
		Examiner Name	Lacourriere, K. Hama, J
		Attorney Docket Number	016930-003712US
Sheet	1	of	

Examiner Signature	John [Signature]	Date Considered	4/26/05
--------------------	------------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/086,294
		Filing Date	February 28, 2002
		First Named Inventor	Nielsen, Loretta
		Art Unit	1635 1632
		Examiner Name	Laseurclere, K. Hama, J.
Attorney Docket Number		016930-003712US	
Sheet	2	of	

NON-PATENT LITERATURE DOCUMENTS


NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
977	AB	Blagosklonny, <i>et al.</i> , "In Vitro Evaluation of A <i>p53</i> -Expressing Adenovirus As An Anti-Cancer Drug," <i>Int. J. Cancer</i> 67:386-392 (1996)	T ²
	AC	Brinckerhoff, <i>et al.</i> , <i>Human Gene Therapy</i> 6:1065-1124 (August 1995)	
	AD	Chang, <i>et al.</i> , "Restoration of the G ₁ Checkpoint and the Apoptotic Pathway Mediated by Wild-type <i>p53</i> Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," <i>Arch Otolaryngol Head Neck Surg.</i> , 123:507-512 (1997)	
	AE	Delia, <i>et al.</i> , <i>Nature Medicine</i> 2(7):724-725 (July 1996)	
	AF	Fujiwara, <i>et al.</i> , "Induction of chemosensitivity in human lung cancer cells <i>in Vivo</i> by adenovirus-mediated transfer of the wild-type <i>p53</i> gene," <i>Cancer Research</i> 54:2287-2291 (1994)	
	AG	Frank, <i>et al.</i> , "Combination <i>E2F-1</i> and <i>p53</i> Gene Transfer Does Not Enhance Growth Inhibition in Human Squamous Cell Carcinoma of the Head and Neck," <i>Clin. Cancer Research</i> 4:2265-2272 (1998)	
	AH	Gallardo, <i>et al.</i> , "Adenovirus-based Transfer of Wild-Type <i>p53</i> Gene Increases Ovarian Tumor Radiosensitivity," <i>Cancer Research</i> 56:4891-4893 (1996)	
	AI	Gjerset, <i>et al.</i> , "Use of Wild-Type <i>p53</i> to Achieve Complete Treatment Sensitization of Tumor Cells Expressing Endogenous Mutant <i>p53</i> ," <i>Molecular Carcinogenesis</i> 14:275-285 (1995)	
	AJ	Gurnani, <i>et al.</i> , "Adenovirus-mediated <i>p53</i> gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer," <i>Cancer Chemother Pharmacol.</i> 44:143-151 (1999)	
	AK	Hehir, <i>et al.</i> , <i>Journal of Virology</i> 70(12):8459-8467 (December 1996)	
	AL	Kalechman, <i>et al.</i> , <i>Journal of Immunology</i> 156(3):1101-1109 (1996)	
	AM	Nguyen, <i>et al.</i> , "Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated <i>p53</i> gene transfer," <i>J. Thorac. Cardiavasc. Surg.</i> 112:1372-1377 (1996)	
↓	AN	Nielsen, <i>et al.</i> , "Adenovirus-mediated <i>p53</i> Gene Therapy and Paclitaxel Have Synergistic Efficacy in Models of Human Head and Neck, Ovarian, Prostate, and Breast Cancer," <i>Clin. Cancer Research</i> 4:835-846 (1998)	

Examiner Signature	John W	Date Considered	4/26/05
-----------------------	--------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional): **Applicant is to place a check mark here if English language Translation is attached.**

Substitute for form 1449B/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

PATENT & TRADEMARK OFFICE

MAR 11 2004

Complete if Known	
Application Number	10/086,294
Filing Date	February 28, 2002
First Named Inventor	Nielsen, Loretta
Art Unit	1635 1632
Examiner Name	Lacourcierie, K. Hama, J.
Attorney Docket Number	016930-003712US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gjt	AO	Ogawa, et al., "Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent," <i>Int. J. Cancer</i> 73:367-370 (1997)	
	AP	Parsels, et al., "Prevention of Fluorodeoxyuridine-Induced Cytotoxicity and DNA Damage in HT29 Colon Carcinoma Cells by Conditional Expression of Wild-Type p53 Phenotype," <i>Molecular Pharmacology</i> 52:600-605 (1997)	
	AQ	Pirollo, et al., "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," <i>Oncogene</i> , 14:1735-1746 (1997)	
	AR	Sandig, et al., "Adenovirally transferred p16 ^{INK4/CDKN2} and p53 genes cooperate to induce apoptotic tumor cell death," <i>Nature Med.</i> , 3:313-319 (1997)	
	AS	Spitz, et al., "In Vivo Adenovirus-Mediated p53 Tumor Suppressor Gene Therapy for Colorectal Cancer," <i>Anticancer Research</i> , 16:3415-3422 (1996)	
	AT	Spitz, et al., "Adenoviral-mediated Wild-Type p53 Gene Expression Sensitizes Colorectal Cancer Cells to Ionizing Radiation," <i>Clin. Cancer Research</i> 2:1665-1671 (1996)	
	AU	Son, et al. "Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> , 91:12669-12672 (1994)	
↓	AV	Tishler, et al., <i>British Journal of Cancer</i> 74(27):S82-S85 (1996)	

60142442 v1

Examiner Signature	<i>Joe H</i>	Date Considered	4/26/05
--------------------	--------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

60142442 v1

Substitute for form 1449A/PTO		Complete if Known	
500 8 0 2005		Application Number	10/086,294
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 28, 2002
(use as many sheets as necessary)		First Named Inventor	Nielsen, Loretta
		Art Unit	1635 1632
		Examiner Name	Lacourciere, K. Hanna, J.
Sheet	1	of	2
		Attorney Docket Number	016930-003712US

Examiner Signature	John W.	Date Considered	4/26/05
-----------------------	---------	--------------------	---------


¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		56382015	Complete If Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>DEMADE</i>	
(use as many sheets as necessary)			
Sheet	2	of	2
		Application Number	10/086,294
		Filing Date	February 28, 2002
		First Named Inventor	Nielsen, Loretta
		Art Unit	1635-1632
		Examiner Name	Lacourciere, K. Hama, J.
		Attorney Docket Number	016930-003712US

Examiner Signature	Joe W	Date Considered	4/26/05
--------------------	-------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>JUN 14 2004</small>			
(use as many sheets as necessary)						
Sheet	3	of				
<i>Patent and Trademark Office</i>						
Complete if Known						
Application Number		10/086,294				
Filing Date		February 28, 2004				
First Named Inventor		Nielsen et al.				
Art Unit		1635 1632				
Examiner Name		Lacourciere, K. Hama, J				
Attorney Docket Number		016930-003712US				

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)		
grt	AA	WO	95/10514 A1	04-20-1995	Schering Corp.
	AB	WO	95/28948 A1	11-02-1995	Univ. Texas
↓	AC	WO	97/23478 A1	07-03-1997	Schering Corp.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	
grt	AD	HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" <i>J. Natl. Cancer Inst.</i> (1996) 88(20):1442-1455.				
	AE	NIELSEN et al., "Combination therapy with the Farnesyl protein transferase inhibitor SCH66338 and SCH58500 (p53 Adenovirus) in preclinical cancer models" <i>Cancer Research</i> (1999) 59:5896-5901.				
↓	AF	TISHLER et al. "Microtubule-active drugs Taxol, Vinblastine, and Nocodazole increase the levels of transcriptionally active p53" <i>Cancer Research</i> (1995) 55:6021-6025.				

60235769 v1

Examiner Signature	Joan Ida	Date Considered	4/26/05
--------------------	----------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

60235769 v1